Drawing for Serial No. 87356042

USPTO serial 87356042

Serial No. 87356042

Reviewed by CopyMark Law Group

Reg. 5290743Status 702Renewal
Filing date
Status date
Registration date
Sep 19, 2017
Examiner
GRIFFIN, JAMES
Law office
TMEG LAW OFFICE 103

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with Serial No. 87356042?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*

Plus Government fees of $650

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

David P. Johnson

David P. Johnson WORKMAN NYDEGGER60 E SOUTH TEMPLESUITE 1000SALT LAKE CITY, UT 84111

Goods and services

ClassDescriptionStatusFirst use
042Pharmaceutical research and development services; Scientific research and development of pharmaceutical preparations; Pharmaceutical research services, namely, developing new uses for pharmaceutical compounds through the use of computer models, animal models, and controlled environments; Contract research services in support of scientific research and development of pharmaceutical preparations; Technical consultancy and services in relation to technical research in the field of pharmaceuticals; Consultancy in relation to scientific research in the field of pharmaceuticals; Providing medical research and scientific research information in the field of medicine and pharmaceuticals; Drug discovery services; Drug use discovery servicesACTIVENov 16, 2013

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 7, 2026E89RTEAS SECTION 8 & 9 RECEIVED—
Sep 19, 2026REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
Nov 9, 2023NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Nov 9, 2023C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Nov 9, 2023APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
May 11, 2023E815TEAS SECTION 8 & 15 RECEIVED—
Sep 19, 2022REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jun 25, 2021COC.CORRECTION UNDER SECTION 7 - PROCESSED—
Jun 7, 2021EROPTEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED—
Mar 30, 2021PRAMPOST REGISTRATION ACTION MAILED - SEC. 7—
Feb 17, 2021APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jan 21, 2021ES7RTEAS SECTION 7 REQUEST RECEIVED—
Sep 19, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 4, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 4, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 14, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 25, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 25, 2017DOCKASSIGNED TO EXAMINER—
Mar 10, 2017MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Mar 9, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 6, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance